On May 5, 2021, CytoDyn announced an agreement to partner with the Albert Einstein Israelite Hospital (AEIH) in Sao Paulo, Brazil for two COVID-19 trials. The COVID-19 trials in Brazil were intended to provide the Brazilian regulatory authority, ANVISA, with the requisite data to consider advancing the availability of leronlimab to thousands of Brazilians infected with COVID-19.

These two Phase 3 trials were planned to be conducted in up to 45 clinical sites.